One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets
Mary KÂ Crow
doi : 10.1136/ard-2022-223741
August 2023 - Volume 82 - 8
Research elucidating the pathogenesis of systemic lupus erythematosus (SLE) has defined two critical families of mediators, type I interferon (IFN-I) and autoantibodies targeting nucleic acids and nucleic acid-binding proteins, as fundamental contributors to the disease.
ChatGPT: when artificial intelligence replaces the rheumatologist in medical writing
Frank Verhoeven, Daniel Wendling, Clément Prati
doi : 10.1136/ard-2023-223936
In this editorial we discuss the place of artificial intelligence (AI) in the writing of scientific articles and especially editorials. We asked chatGPT « to write an editorial for Annals of Rheumatic Diseases about how AI may replace the rheumatologist in editorial writing ». chatGPT's response is diplomatic and describes AI as a tool to help the rheumatologist but not replace him.
Country-level socioeconomic status relates geographical latitude to the onset of RA: a worldwide cross-sectional analysis in the METEOR registry
Sytske Anne Bergstra, Alexandre Sepriano, Arvind Chopra, Lai-Ling Winchow, David Vega-Morales, Karen Salomon-Escoto, Xanthe M E Matthijssen, Robert BM Landewé
doi : 10.1136/ard-2023-224080
Objective Age at rheumatoid arthritis (RA) onset varies by geographical latitude. We have investigated to what extent differences in patient-specific factors and country-level socioeconomic indicators explain this variability.
Irreversible covalent Bruton’s tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial
Tsutomu Takeuchi, Sakae Tanaka, Mitsuru Murata, Yoshiya Tanaka
doi : 10.1136/ard-2022-223759
Objective To examine the efficacy and safety of TAS5315, an irreversible covalent Bruton’s tyrosine kinase inhibitor, in Japanese patients with rheumatoid arthritis (RA) refractory to methotrexate.
Identification of MYH9 as a key regulator for synoviocyte migration and invasion through secretome profiling
Saseong Lee, Eunbyeol Choi, Sehyun Chae, Jung Hee Koh, Yoolim Choi, Jung Gon Kim, Seung-Ah Yoo, Daehee Hwang, Wan-Uk Kim
doi : 10.1136/ard-2022-223625
Objectives ‘Invasive pannus’ is a pathological hallmark of rheumatoid arthritis (RA). This study aimed to investigate secretome profile of synovial fibroblasts of patients with RA (RA-FLSs), a major cell type comprising the invasive pannus.
Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies
Walter Reinisch, Wayne Hellstrom, Radboud J E M Dolhain, Suresh Sikka, René Westhovens, Rajiv Mehta, Timothy Ritter, Ursula Seidler, Oleksandr Golovchenko, Vladimir Simanenkov, Olena Garmish, Sławomir Jeka, Radka Moravcová, Vijay Rajendran, Franck-Olivier Le Brun, Sarah Arterburn, Timothy R Watkins, Robin Besuyen, Dirk Vanderschueren
doi : 10.1136/ard-2023-224017
Objectives The phase 2 MANTA and MANTA-RAy studies aimed to determine if the oral Janus kinase 1 preferential inhibitor filgotinib affects semen parameters and sex hormones in men with inflammatory diseases.
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications
Mark D Russell, Christopher Stovin, Edward Alveyn, Olukemi Adeyemi, Chun Kit David Chan, Vishit Patel, Maryam A Adas, Fabiola Atzeni, Kenrick K H Ng, Andrew I Rutherford, Sam Norton, Andrew P Cope, James B Galloway
doi : 10.1136/ard-2023-224049
Objectives To estimate the association of Janus kinase inhibitors (JAKi) with the incidence of malignancy, compared with placebo, tumour necrosis factor (TNF)-α inhibitors (TNFi) and methotrexate.
Is methotrexate safe for men with an immune-mediated inflammatory disease and an active desire to become a father? Results of a prospective cohort study (iFAME-MTX)
Luis Fernando Perez-Garcia, Esther Röder, Bouwe P Krijthe, Laura JC Kranenburg-van Koppen, Roxanne van Adrichem, Els Zirkzee, Pieter H Griffioen, Kris Peeters, Marry Lin, Eduard A Struys, Gerrit Jansen, Martijn BA van Doorn, Robert de Jonge, Gert R Dohle, Radboud JEM Dolhain
doi : 10.1136/ard-2023-224032
Introduction Current scientific evidence guiding the decision whether men with an active desire to become a father should be treated with methotrexate (MTX) remains controversial. We aimed to prospectively evaluate the testicular toxicity profile of MTX focusing on several markers of male fertility, including semen parameters and sperm DNA fragmentation index (sDFI). As a secondary outcome, we aimed to evaluate whether MTX-polyglutamates can be detected in spermatozoa and seminal plasma and to evaluate the enzymatic activity in spermatozoa of folylpolyglutamate synthetase (FPGS).
Distinct immune modulatory roles of regulatory T cells in gut versus joint inflammation in TNF-driven spondyloarthritis
Koen Venken, Matthias Jarlborg, Tine Decruy, Céline Mortier, Carolien Vlieghe, Elisabeth Gilis, Ann-Sophie De Craemer, Julie Coudenys, Isabelle Cambré, Devan Fleury, Alexander Klimowicz, Filip Van den Bosch, Anne Hoorens, Triana Lobaton, Sytze de Roock, Tim Sparwasser, Gerald Nabozny, Peggy Jacques, Dirk Elewaut
doi : 10.1136/ard-2022-223757
Objectives Gut and joint inflammation commonly co-occur in spondyloarthritis (SpA) which strongly restricts therapeutic modalities. The immunobiology underlying differences between gut and joint immune regulation, however, is poorly understood. We therefore assessed the immunoregulatory role of CD4+FOXP3+ regulatory T (Treg) cells in a model of Crohn’s-like ileitis and concomitant arthritis.
Transcriptional derepression of CHD4/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies
Iago Pinal-Fernandez, Jose Cesar Milisenda, Katherine Pak, Sandra Muñoz-Braceras, Maria Casal-Dominguez, Jiram Torres-Ruiz, Stefania Dell'Orso, Faiza Naz, Gustavo Gutierrez-Cruz, Yaiza Duque-Jaimez, Ana Matas-Garcia, Joan Padrosa, Francesc J Garcia-Garcia, Mariona Guitart-Mampel, Gloria Garrabou, Ernesto Trallero-Araguás, Brian Walitt, Julie J Paik, Jemima Albayda, Lisa Christopher-Stine, Thomas E Lloyd, Josep Maria Grau-Junyent, Albert Selva-O'Callaghan, Andrew Lee Mammen
doi : 10.1136/ard-2023-223873
Objectives Myositis is a heterogeneous family of diseases including dermatomyositis (DM), immune-mediated necrotising myopathy (IMNM), antisynthetase syndrome (AS) and inclusion body myositis (IBM). Myositis-specific autoantibodies define different subtypes of myositis. For example, patients with anti-Mi2 autoantibodies targeting the chromodomain helicase DNA-binding protein 4 (CHD4)/NuRD complex (a transcriptional repressor) have more severe muscle disease than other DM patients. This study aimed to define the transcriptional profile of muscle biopsies from anti-Mi2-positive DM patients.
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients
Sara Monti, Alessandra Milanesi, Catherine Klersy, Alessandro Tomelleri, Lorenzo Dagna, Corrado Campochiaro, Nicola Farina, Francesco Muratore, Elena Galli, Chiara Marvisi, Milena Bond, Alvise Berti, Roberto Bortolotti, Roberto Padoan, Franco Schiavon, Mara Felicetti, Carlotta Nannini, Fabrizio Cantini, Alessandro Giollo, Maurizio Rossini, Edoardo Conticini, Bruno Frediani, Fabrizio Conti, Roberta Priori, Marco Sebastiani, Giulia Cassone, Luca Quartuccio, Elena Treppo, Silvano Bettio, Ariela Hoxha, Marco Lovisotto, Giacomo Emmi, Irene Mattioli, Pietro Leccese, Roberto Caporali, Lorenza Maria Argolini, Rosario Foti, Elisa Visalli, Michele Colaci, Carlo Salvarani, Carlomaurizio Montecucco
doi : 10.1136/ard-2023-223895
Background Immune and vascular ageing are proposed risk factors for giant cell arteritis (GCA). Data on the impact of age at diagnosis of GCA on the clinical presentation and course of the disease are scarce.
Points to consider: EULAR–UEMS standards for the training of European rheumatologists
Alessia Alunno, Tadej Avcin, Catherine Haines, Sofia Ramiro, Francisca Sivera, Sara Badreh, Xenofon Baraliakos, Johannes W J Bijlsma, Frank Buttgereit, Kaushik Chaudhuri, Jose A P Da Silva, Jean Dudler, Ricardo J O Ferreira, Tania Gudu, Eric Hachulla, Mette Holland-Fischer, Annamaria Iagnocco, Tue Wenzel Kragstrup, György Nagy, Vasco C Romão, Simon R Stones, Marloes van Onna, Christopher J Edwards
doi : 10.1136/ard-2023-223941
Background Postgraduate rheumatology training programmes are already established at a national level in most European countries. However, previous work has highlighted a substantial level of heterogeneity in the organisation and, in part, content of programmes.
Homonymous hemianopsia and headache with mass-like lesion
Kuniyuki Aso, Yuichiro Fujieda, Tatsuya Atsumi
doi : 10.1136/ard-2022-223686
High frequency of long-term opioid use among patients with rheumatic and musculoskeletal diseases initiating opioids for the first time
Yun-Ting Huang, David A Jenkins, Niels Peek, William G Dixon, Meghna Jani
doi : 10.1136/ard-2023-224118
Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells
Christina Bergmann, Fabian Müller, Jörg H W Distler, Andrea-Hermina Györfi, Simon Völkl, Michael Aigner, Sascha Kretschmann, Hannah Reimann, Thomas Harrer, Nadine Bayerl, Sebastian Boeltz, Andreas Wirsching, Jule Taubmann, Wolf Rösler, Bernd Spriewald, Jochen Wacker, Armin Atzinger, Michael Uder, Torsten Kuwert, Andreas Mackensen, Georg Schett
doi : 10.1136/ard-2023-223952
Familial systemic lupus erythematosus associated with a loss-of-function mutation in TRPC6
Dandan Chen, Hanlin Yin, Le Zhang, Fubin Li, Liangjing Lu
doi : 10.1136/ard-2022-223824
Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry
Ronald F van Vollenhoven, Sander W Tas, Michael T Nurmohamed
Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis� by van Vollenhoven et al
Jeffrey A Sparks, Zachary S Wallace, Andrea M Seet, Philip C Robinson, Pedro M Machado, Jinoos Yazdany
Correspondence on ‘Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients’
Yudong Liu
Response to: Correspondence on ‘Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients’ by Liu
Marvin J Fritzler, Uriel Trahtemberg
Challenge of diagnosing ANCA-associated vasculitis during COVID-19 pandemic: a missed ‘window of opportunity’
Alessandro Giollo, Riccardo Bixio, Davide Gatti, Ombretta Viapiana, Luca Idolazzi, Christian Dejaco, Maurizio Rossini
Correspondence on ‘Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: case–control study’
Martin Sebastian Winkler, Peter Korsten, Claudia Binder, Björn Tampe
Correspondence on ‘Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level and patient global assessment’
Ricardo J O Ferreira, Paco M J Welsing, Johannes WG Jacobs, Laure Gossec, Mwidimi Ndosi, Pedro M Machado, Désirée van der Heijde, Jose AP Da Silva
Response to: Correspondence on ‘Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment’ by Ferreira et al
David Felson, Diane Lacaille, Michael P LaValley, Daniel Aletaha
Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’
Stefan Siebert, Helena Marzo-Ortega
Response to: Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physicianreported spondylitis’?’ by Siebert and Marzo-Ortega
Juergen Braun, Robert BM Landewé
Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’
Dafna D Gladman, Philip J Mease, Paul Bird, Enrique R Soriano, Soumya D Chakravarty, May Shawi, Frederic Lavie, Cinty Gong, Evan Leibowitz, Denis Poddubnyy, Lai-Shan Tam, Philip S Helliwell, Arthur Kavanaugh, Atul A Deodhar, Mikkel Østergaard, Xenofon Baraliakos
Response to: Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ by Gladman
Robert BM Landewé, Juergen Braun
Correspondence on “New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE�
Guillermo J Pons-Estel, Manuel F. Ugarte-Gil, Guillermina B Harvey, Bernardo A Pons-Estel, Graciela S Alarcón
Response to: Correspondence on “New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE� by Pons-Estel et al
Laura Whittall-Garcia, Dafna D Gladman, Murray Urowitz, Jiandong Su, Zahi Touma, Sindhu R Johnson
Correspondence on “Update on the diagnosis and management of systemic lupus erythematosus�
Zhuochao Zhou, Yijun You, Fan Wang, Yue Sun, Jialin Teng, Honglei Liu, Xiaobing Cheng, Yutong Su, Hui Shi, Chengde Yang, Junna Ye
Response to: Correspondence on “Update on the diagnosis and management of systemic lupus erythematosus� by Zhou et al
Antonis Fanouriakis, Nikolaos Tziolos, George Bertsias, Dimitrios T Boumpas
Correspondence on “European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance�
Xavier Bossuyt, Walter Fierz, Pier Luigi Meroni
Response to: Correspondence on “European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance� by Bossuyt et al
Martin Aringer, Karen Costenbader, Nicolai Leuchten, Thomas Dörner, Sindhu R Johnson
Correspondence on ‘Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors’
Dimitrios Patoulias
Response to: Correspondence on ‘Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors’ by Patoulias
Marcus Säemann, Andreas Kronbichler
Correspondence on ‘2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis’ by Joanna C Robson et al and ‘2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis’
Victor Román Pimentel-Quiroz, Manuel Francisco Ugarte-Gil, Graciela S Alarcón
Response to: Correspondence on ‘2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis’ by Joanna C Robson et al and ‘2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis’ by Pimentel-Quiroz et al
Peter C Grayson, Joanna C Robson, Ravi Suppiah, Cristina Ponte, Richard A Watts, Raashid A Luqmani, Peter A Merkel
Where are the women ‘Heroes and Pillars of Rheumatology’?
Nicola Dalbeth, Tuhina Neogi
Response to: Where are the women ‘Heroes and Pillars of Rheumatology’?
Josef SÂ Smolen
